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Abstract
Background: The development of suture hole bleeding at peripheral arterial bypass anastomoses
using PTFE graft prostheses is a common problem in peripheral vascular surgery. Traditionally the
problem is managed by compression with surgical swabs and reversal heparin or by using several
haemostatic device (e.g. different forms of collagen, oxidized cellulose, gelatine sponge,
ethylcyanoacrylate glue or fibrin) with various success. Preclinical data suggest that the haemostatic
effect of collagen is stronger than that of oxidized cellulose, but no direct clinical comparison of
their hemostatic performance has been published so far.
Design: This randomized, controlled, prospective trial evaluates the haemostatic effect of Lyostypt
versus Surgicel in arterial bypass anastomosis. 28 patients undergoing an elective peripheral
vascular reconstruction due to peripheral vascular disease will be included. Suture hole bleeding
occurring at the arterial bypass anastomosis using a PTFE prostheses will be stopped by the
application of Lyostypt and/or Surgicel. The proximal anastomoses will be randomized
intraoperatively. The patients will be allocated into 4 different treatment groups. Group1 Lyostypt
distal/Surgicel proximal; Group 2: Lyostypt proximal/Surgicel distal; Group 3: Surgicel distal and
proximal; Group 4: Lyostypt distal and proximal. Primary endpoint of the study is time to
haemostasis. Secondary endpoints are the number of intraoperatively used haemostatic devices,
postoperative mortality within 30 days as well as the intraoperative efficacy rating of the two
devices evaluated by the surgeon. As a safety secondary parameter, the local and general
complication occurring till 30 ± 10 days postoperatively will also be analysed. After hospital
discharge the investigator will examine the enrolled patients again at 30 days after surgery.
Discussion: The COBBANA trial aims to assess, whether the haemostatic effect of Lyostypt is
superior to Surgicel in suture hole bleedings of arterial bypass anastomoses.
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Background
Rationale
Haemostasis in peripheral vascular surgery is made more
difficult by the need for direct arterial and arterial graft
suturing as well as by systemic anticoagulation to prevent
thrombosis during periods of vascular occlusion. Poly-
tetrafluorethylene (PTFE) is one of the most frequently
used graft materials for vascular replacement or bypass in
the case when no autologous venae are available [1].
However, the insufficient elasticity of PTFE and its poros-
ity promote the development of suture hole bleeding [2,3]
which can cause considerable loss of blood and prolonga-
tion of operations due to additional suturing with danger
of iatogenic stenosis [2].
There are several medical risk factors that can affect bleed-
ing time and haemostasis, such as hypertension, chronic
liver disease, or renal failure [4]. The problem of bleeding
from suture holes remains a serious drawback to the use
of PTFE. Suture line bleeding in arterial surgery is prima-
rily controlled with precise suture technique, including
use of fine suture material and needle [5]. To assist with
control of residual bleeding after suturing of arterial oper-
ative sites, various topical haemostatic aids are in use. Tra-
ditionally the problem of suture hole bleeding is managed
by compression with surgical swabs and reversal heparin.
Other attempts to control suture hole bleeding have also
been used with various success, such as ethylcyanoacyrlate
glue [6], different forms of collagen [7-10], oxidized cellu-
lose [9,11], or gelatine sponge [9] or fibrin [12,13].
Another approach to topical haemostasis is the use of an
agent that enhances or accelerates formation of autoge-
nous thrombus, such as topical thrombin, which can be
used in conjunction with scaffolding-type agents [14,15].
In the COBBANA trial the collagen based haemostat
Lyostypt will be compared with Surgicel which is the lead-
ing standard and is commonly used for this indication.
Purpose
This study is designed to demonstrate the superiority of
Lyostypt to oxidized cellulose (Surgicel) for haemostasis
of suture hole bleeding in arterial bypass anastomoses
after vascular reconstruction. Lyostypt is an absorbable,
wet stable collagen compress made of collagen fibrils of
bovine origin. Collagen leads to thrombocyte adhesion
and to activation of coagulation factor XII. Therefore col-
lagen is very effective in haemostasis. Collagen is cell-
friendly whereas other haemostats significantly disturb
cell growth. Advantages of collagen fleece are fast induc-
tion of haemostasis, low tissue reaction and fast absorp-
tion [16]. Furthermore, collagen was shown to be the best
overall haemostatic agent in microvascular surgery.
Authors concluded that collagen fleece establish faster
haemostasis than oxidized cellulose and that it was
resorbed faster than oxidized cellulose [16].
Need for the study
The ideal haemostat should be easy to use with good risk-
benefit and cost-benefit ratios. Such an agent should be
easily applied in a controlled fashion, highly predictable
in creating haemostasis, nontoxic and must not have an
adverse affect on anastomostic patency, increased anasto-
motic strength would also be beneficial.
Preclinical data strongly suggest that haemostats made of
collagen have a stronger haemostatic effect than haemo-
stats made of oxidized cellulose [16]. While both investi-
gational devices have been in clinical use for many years
[7-11], no direct clinical comparison of their haemostatic
performance has been published so far.
Methods/Design
Objectives of the study
The aim of this study is to evaluate the haemostatic effect
of Lyostypt and Surgicel in arterial bypass anastomosis.
The measurement of the bleeding time of suture hole
bleeding of arterial bypass anastomoses is considered as a
suitable efficacy parameter for the assessment of the hae-
mostatic effect. It is expected that the treatment of suture
hole bleeding of arterial bypass anastomoses with
Lyostypt will reduce the time to haemostasis in compari-
son to the treatment with Surgicel (primary objective).
Local complication and general complication rates occur-
ring till 30 ± 10 days after surgery and handling character-
istics of the different devices will also be assessed
(secondary objectives).
Primary endpoint
The primary endpoint of the trial is the time to haemosta-
sis (period from release of the cross-clamping to the
moment the wound is completely dry or at least suffi-
ciently dry to finalise the operation without additional
measures for haemostasis as judged by the surgeon). If
haemostasis is not achieved within 3 minutes, a second
equal device is applied for another 2 minutes. If haemos-
tasis is still insufficient, the surgeon will wait for another
5 minutes, before considering other methods. When hae-
mostasis is not achieved after 10 minutes, it is considered
a study failure.
Secondary endpoint
- Local and general complication rate till 30 ± 10 days after
surgery
- The number of haemostatic devices used
- Intraoperative efficacy rating of each device, (surgical
handling characteristics, tissue adhesion of each device)Trials 2009, 10:91 http://www.trialsjournal.com/content/10/1/91
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- Postoperative mortality until 30 days after surgery
- Recurrence of bleeding at the anastomosis,
- Analysis of adverse events
Design
This is a randomized, controlled, prospective study to
evaluate the haemostatic effect of Lyostypt versus Surgicel
in arterial bypass anastomoses.
In this study, 28 eligible patients with a peripheral arterial
bypass following peripheral vascular reconstruction, will
be treated with the investigational devices during the pilot
phase. There will be 4 treatment groups: Group 1 and 2
will receive both products one at the distal and the other
at the proximal anastomosis. In group 3 and 4 the same
haemostat will be applicated at both anastomoses either
Lyostypt or Surgicel. The proximal bypass anastomosis
will be randomized for the application of the haemostat.
After discharge from the hospital the investigator will
examine the patients at 30 ± 10 days after surgery (figure
1 and table 1).
By employing a sequential adaptive statistical design, the
results of the pilot phase will be analysed and the appro-
Table 1: Flow Chart COBBANA Trial.
Visit 1 (Screening) Visit 2 (OP) Visit 3 
(2 ± 1 days post OP)
Visit 4 
(Day of discharge)
Visit 5 
(30 ± 10 Days post 
OP)
Patient information X
Informed consent X
Demographic data* X
Smoker/non-smoker X
Inclusion/exclusion X
Past medical history X
Physical examination X X X 1) X 1) X 1)
Surgery X
Time to obtain hemostasis X
Deviation from surgical 
procedures as described in 
the protocol
X
Number of used devices X
Intraoperative handling of 
the devices
X
Recurrence of bleeding X X X x
Adverse Event/Serious 
Adverse Event
XX X X
Local and general 
complication/re-operation
XX X X
Mortality X
* date of birth, gender, weight, height,
1) of the operational woundTrials 2009, 10:91 http://www.trialsjournal.com/content/10/1/91
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priate total number of cases determined in a second phase
(see section on sample size). If the second phase of this
study will be conducted, patients will be recruited and
treated as already described for the pilot phase.
Eligibility
Detailed inclusion and exclusion criteria are specified in
table 2. Patients are screened consecutively for eligibility
in the participating centre after approval of the study pro-
tocol by the local ethics committee. A contract has been
signed by Aesculap AG and the participating centre for
correct conduction of the trial according to Good Clinical
Practice. The participating surgeons performing the inter-
vention have been instructed by detailed manuals.
Consent
The participating centre recruits trial patients from its
patients who are scheduled for an elective implantation of
PTFE graft for peripheral revascularization, who develop
suture hole bleeding of arterial bypass anastomoses fol-
lowing peripheral vascular reconstruction. All patients
who seem to fit to the in- and exclusion criteria will be
asked whether they are willing to participate in the COB-
BANA trial and they will be informed about the purpose
of the trial, the operation modalities, data management,
and their possibilities and risks. Interested patients will be
screened according to inclusion and exclusion criteria and
included into the trial after written Informed Consent has
been obtained from the patient.
Randomization
Upon inclusion in the study the patient will receive a
unique identification number. Intraoperatively their anas-
tomoses will be randomized to receive either Lyostypt or
Surgicel by opening sealed opaque envelopes containing
the information which device should be used. The combi-
nations proximal and distal: Lyostypt, proximal: Lyostypt/
distal: Surgicel, proximal: Surgicel/distal: Lyostypt, proxi-
mal and distal: Surgicel will occur in equal quantities (fig-
ure 2).
The envelopes will be prepared by the sponsor with bal-
anced distribution of either Lyostypt or Surgicel according
to a randomization list provided by the statistician. The
randomization list is sealed and kept under lock and key
until data queries are resolved and the data base is locked.
The envelopes will be assigned to the patients in a chron-
ological order. The envelope contains the devices and also
two labels with a randomisation number and the infor-
mation about the device which was applied to the proxi-
mal and distal anastomosis, which must be attached to
the CRF and the surgery form.
Intervention
In the current trial the surgical procedure is standardised
to achieve a better comparability of the outcome. For each
surgical intervention a Polytetrafluoro-ethylene vascular
prostheses from the same manufacture (PTFE prostheses,
thin walled, diameters 4-10 mm) will be surgical
implanted in accordance with the standard practice of the
investigative centre using a non-absorbable polypropyl-
ene suture material USP 5-0, USP 6-0 for the anastomotic
suture line. The investigator will perform the distal anas-
tomosis first. The clamp will be opened to check for suture
hole bleeding. If bleeding occurs, the clamp will be closed
and a randomization envelope containing the study mate-
rial will be opened. The devices will be cut into half.
Thereafter, the clamp at the distal anastomosis will be
removed and a stopwatch will be started and the rand-
omized device will be placed circumferentially around the
anastomosis and applied for three minutes. The suture
line is monitored by the investigator and the time
required to achieve complete sealing is recorded with a
stopwatch. If haemostasis is not achieved after 3 minutes
a new equal device is placed around the anastomosis for
another 2 minutes and the time to obtain haemostasis is
measured with a stopwatch. In the case that suture hole
bleeding has not stopped after 5 minutes the investigator
will wait for another 5 minutes to achieve haemostasis.
Subjects are considered treatment failures if suture hole
bleeding could not be controlled within 10 minutes or if
additional interventions are required to achieve sealing.
Every application of a new device will be recorded with
type of device and time after clamp removal.
If haemostasis is achieved at the distal anastomosis the
surgeon will perform the proximal anastomosis. Follow-
ing the anastomotic procedure the clamp at the prosthesis
COBBANA Trial: Schedule of the visits Figure 1
COBBANA Trial: Schedule of the visits. This figure 
represents a flow chart of all visits conducted in the COB-
BANA trial. The figure also indicates when the primary and 
secondary endpoints are collected.
Visit 1: Screening
Visit 2: (day of surgery)
Peripheral bypass reconstruction
Visit 3: (day 2 after surgery)
Visit 4: (day of discharge)
Visit 5: (30 ±10 days after surgery
Defines primary
and secondary
endpoint
Defines secondary
endpointTrials 2009, 10:91 http://www.trialsjournal.com/content/10/1/91
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is released. If suture hole bleeding is present, the clamp
will be closed. The device according to the randomization
procedure will be prepared (if no bleeding at the distal
anastomosis had occurred, the randomization envelop
has to be opened) and the clamp will be removed and a
stopwatch will be started. The randomized device will be
placed circumferentially around the proximal anastomo-
sis and applied for three minutes. If haemostasis is not
achieved after 3 minutes a new equal device is placed
around the anastomosis for another 2 minutes and the
time to obtain haemostasis is measured with a stopwatch.
In the case that suture hole bleeding has not stopped after
5 minutes the investigator will wait for another 5 minutes
to achieve haemostasis. Subjects are considered treatment
failures if suture hole bleeding could not be controlled
within 10 minutes or if additional interventions are
required to achieve sealing. Every application of a new
device will be recorded with type of device and time after
clamp removal. After achieving haemostasis at the proxi-
mal anastomosis the proximal clamp will be removed and
the surgical procedure will be finished.
Study Device
The investigational products are the haemostats Lyostypt
and Surgicel (= Tabotamp). For Lyostypt, the size 5 cm ×
8 cm and for Surgicel, the size 5 cm × 7,5 cm will be sup-
plied to the study centre.
Lyostypt
Lyostypt is an absorbable wet-stable collagen compress
made of collagen fibrils of bovine origin. Collagen leads
to thrombocyte adhesion and to activation of coagulation
factor XII. Lyostypt collagen haemostatic fleece is indi-
cated for capillary bleedings, parenchymal haemorrhages,
oozing wound haemorrhages, for the local haemostasis in
haemodialysis and as a supportive method for other tech-
niques in haemostasis. Lyostypt achieves haemostasis very
swiftly, it can be removed easily, it can be applied endo-
scopically and it can be combined with fibrin glue and
antibiotics (16). Collagen haemostats showed low tissue
reaction, fast resorption and good biocompatibility (15).
Lyostypt is y-sterilized.
Surgicel/Tabotamp
Surgicel absorbable haemostat is a sterile absorbable knit-
ted fabric prepared by the controlled oxidation of regener-
ated cellulose. The fabric is white with a pale yellow cast
and has a faint caramel-like aroma. It is strong and can be
sutured or cut without fraying. After Surgicel has been sat-
urated with blood, it swells into a brownish or black gelat-
inous mass which aids in the formation of a clot, thereby
serving as a haemostatic adjunct in the control of local
haemorrhage. When used properly in minimal amounts
Surgicel haemostat is absorbed from sites of implantation
with practically no tissue reaction.
Surgicel is used adjunctively in surgical procedures to
assist in the control of capillary, venous and small arterial
haemorrhage when ligation, suturing or other conven-
tional methods of control are impractical or ineffective.
Sample size
The study is planned in a two-step design. Initially, 28
patients will be enrolled and a test at the α1 = .0102 will
be performed. The exact number will depend on the
number of bleeding anastomoses, as patients will be
Table 2: Eligibility Criteria.
INCLUSION CRITERIA EXCLUSION CRITERIA
• Patients > 18 years ￿ Emergency surgery
￿ Informed Consent ￿ Patients with coagulopathy or uremia
￿ Indication for a peripheral vascular reconstruction due to peripheral 
vascular disease
￿ Participating in another trial with interfering endpoints
￿ Suture hole bleeding of peripheral arterial bypass anastomosis using 
PTFE graft
￿ Patients requiring continuous postoperative anticoagulation
￿ Reoperation within one month at the same location
￿ Pregnant and breastfeeding women
￿ Known or suspected allergies or hypersensitivity to any of the used 
devices
￿ Severe comorbidity (ASA >4)
￿ Life expectancy less than 12 months
￿ Current immunsuppressive therapy
￿ Chemotherapy within last 4 weeks
￿ Severe psychiatric or neurologic diseases
￿ Lack of compliance
￿ Drug- and/alcohol-abuse
￿ Inability to understand and to follow the instructions given by the 
investigatorTrials 2009, 10:91 http://www.trialsjournal.com/content/10/1/91
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accrued until 56 applications of a randomized device have
been recorded. The main test will be carried out as a
parameter test in the model outlined in section statistical
analysis.
The trial will be stopped for rejection of the null hypothe-
sis if the one-sided p-value is lower than α1, and stopped
for futility if it is higher than .50. The level of significance
for the final analysis is set to α2 = 0.00380/p1, where p1 is
the p-value corresponding to the one-sided test of the pri-
mary criterion from the interim analysis, following the
approach of Bauer and Köhne [17]. For the second part of
the trial, the sample size will be recalculated and will lie
between 12 and 72.
This procedure maintains the overall significance level of
2.5 per cent and a power of the one-sided test as described
in statistical analysis at 80 per cent. This result was
obtained by simulation based on 300 replicates.
Statistical Analysis
The primary criterion is the time to haemostasis at an
anastomosis. For the evaluation of the primary criterion,
the single anastomosis is treated as the observational unit.
Time to haemostasis, which will be censored at 10 min-
utes, will be included as the response parameter in an
accelerated failure time regression model [18] assuming a
Weibull distribution for bleeding time with the following
explanatory parameters included: treatment on anasto-
mosis (Lyostypt vs. Surgicel), treatment on opposite anas-
tomosis (Lyostypt vs. Surgicel), site of anastomosis
(proximal vs. distal), and center. Subject will be included
as a shared frailty term with lognormal distribution. The
formal null hypothesis to be tested at a level of α = 0.025
(spent over two tests carried out in different stages) is:
"Anastomosis bleeding time under Lyostypt is at least as
long as under Surgicel".
Haemostasis during 5 and 10 minutes, local and general
complication rate till 30 ± 10 days after surgery, the
number of used haemostatic devices minus one will be
modelled in a logistic mixed regression model using the
same covariates as for the main model. Subject will enter
the analysis as a random effect. If model instabilities occur
due to overspecification (signified by a condition number
of the design matrix of more than 40), the term "treatment
on opposite anastomosis" and possibly the center effect
will be dropped.
The intraoperative efficacy rating scale of each device will
be modeled separately for the 4 step ranking scale of adhe-
sion and the 5 step ranking scale of handling, using a
logistic mixed model of ordinal responses using the same
covariates as in the main model as fixed and surgeon and
subject as random effects. Postoperative mortality will be
described individually in the final report. Adverse events
which are recorded will be reported casuistically, men-
tioning the haemostypt actually applied at the distal and
proximal site.
Interim Analysis
One interim analysis is planned. The number of patients
to be included after interim analysis will be calculated
based on the p-value of the parameter test in the model for
the main parameter outlined above based on the adaptive
design proposed by Bauer and Köhne [17]. The interim
analysis will be used to test the distributional assumption
of a Weibull distribution for the bleeding time (using the
Anderson-Darling test statistics for the residuals for a test
at the 10 per cent level), in order to perform the analysis
on the rest of the patient using a more appropriate distri-
bution.
Clinical site and safety aspects
Sites are selected according to their experience in periph-
eral arterial bypass reconstruction, their clinical research
experience, to the number of eligible patients operated in
the indicated intervention per year and to their willing-
ness to adhere to clinical trial protocol. The participating
centre is mentioned at the end of this paper.
As Lyostypt and Surgicel are used locally a systemic effect
can be excluded, only adverse events that affect the
peripheral arterial bypass region during the end of opera-
tion and the last visit of the patient will be documented
on the AE form in the CRF. All suspected unexpected seri-
ous adverse events and reactions (SUSAR) will be reported
from the principal investigator to the sponsor. The spon-
sor will inform the leading ethical committee about the
unexpected SAEs and SUSARs. For safety analysis the inci-
COBBANA Trial: CONSORT Flow Chart Figure 2
COBBANA Trial: CONSORT Flow Chart. Flow Chart 
of patients according to CONSORT.
Eligibility
(n= 32)
Exclusion (n = 4)
Intra-operative Drop-out
No bleeding occurr
Randomization
(n = 28)
Distal/  Proximal Distal/Proximal  Distal/Proximal Distal/Proximal
Lyostypt/Surgicel Surgicel/Lyostypt  Surgicel/Surgicel  Lyostypt/Lyostypt
(n = 7)   (n = 7)               (n = 7)                        (n = 7)
Analysed Analysed  Analysed  Analysed
30d postop  30d postop  30d postop  30d postop
(n = 7)    (n = 7)               (n = 7)                     (n = 7)Trials 2009, 10:91 http://www.trialsjournal.com/content/10/1/91
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dence of AE and SAE occurring in the peripheral arterial
bypass region will be analysed. Patients may withdraw
from the study at any time either at their own request or
at the request of the principal investigator.
Trial organization, quality control, registration and ethical 
aspects
The COBBANA trial is initiated and sponsored by B|Braun
Aesculap and conducted by Aesculap AG. The Coordinat-
ing Centre of Clinical Trials (KKS) in Heidelberg is
responsible for the data management and the biometrics.
Monitoring is done by a independent person of Aesculap
AG who will visit the investigational site at regular inter-
vals to verify adherence to the protocol and perform
source data verification. Aesculap AG is responsible for
the management and the registration (Identifier Number
NCT00837954, http://www.clinicaltrial.gov). Enrolment
must be reported immediately by the investigator by fax
on prepared forms to the sponsor. Quality assurance will
be done in cooperation with the KKS in Heidelberg. The
trial is performed according to the Declaration of Helsinki
in its current German version and the Good Clinical Prac-
tice (GCP). Before the start of the trial the independent
ethics committee of the Landesärztekammer Hessen gave
their positive vote on 3rd February 2009. The study was
registered on 5th February 2009.
Current status and duration of the trial
The study protocol for the trial was completed on 5th
November 2008. Following completion of the contract
the study was initiated on 28th January 2009. Currently
one centre recruits patients with the goal of 28 patients.
After receiving the positive ethics vote the first patients
was randomized on 26th February 2009. Assuming an
overall enrolment of 3 patients per month, the end of
recruitment is expected for October 2009.
Discussion
For topical haemostasis bone wax, and various other top-
ical haemostatic agents (powdered oxidized cellulose in
polyethylene glycol wax, oxidized cellulose, gelatine
paste, microfibrillar collagen, gelatine sponge soaked in
thrombin) are currently in use [19]. Haemostasis is
achieve through the physical, mechanical (bone wax, gel-
atine, oxidized cellulose) and chemical effect (microfibril-
lar collagen) of these materials [15,19]. Bone wax is non-
absorbable whereas the other haemostatic agents are
absorbed within days and weeks. Complications like aller-
gic reactions, infections, granulomas and interference
with bone healing have been noticed only rarely after the
application of theses materials [15].
Only a few controlled clinical trials exist that compare two
or more haemostatic agents [9,20-27]. Voormolen et al.
[28] conducted an experimental study in rabbits in which
cerebral lesions were made and filled with oxidized regen-
erated cellulose and collagen fleece. Results showed lower
bleeding times for microfibrillar collagen with quicker
resorption rate than for traditional oxidized regenerated
cellulose. They concluded that collagen fleece established
faster haemostasis and that it was faster resorbed than oxi-
dized cellulose. Rybock et al. [29] compared the haemo-
static properties of microfibrillar collagen versus a
gelatinfoam in suction-evacuation lesions of the canine
cortex. Microfibrillar collagen was found to be faster and
more effective than the gelatine foam in achieving hae-
mostasis. Wagner et al. [30] quantitatively compared six
commonly used topical haemostatic agents in terms of
their ability to mediate platelet aggregation, deposition
and activation in a series of in vitro tests. They presented
an overall activity ranking of the materials used: collagen
>gelatine>oxidized regenerated cellulose. Finn et al. [31]
concluded that microfibrillar collagen, oxidized regener-
ated cellulose, and gelatine foam might be adequately
used in iliac procurement, whereas bone wax seems to be
contraindicated. Microfibrillar collagen was showed to be
the best overall haemostatic agent in microvascular sur-
gery [32]. The prospective randomized neurosurgical trial
reported by Krüger et al. [25] showed superior haemo-
static effect of a collagen fleece (Lyostypt) compared with
gelatine foam.
Suture hole bleeding in patients undergoing vascular
reconstruction with polytetrafluoroethylene grafts is a
considerable problem in vascular surgery. Various animal
and clinical studies evaluating the haemostatic efficacy of
different materials demonstrated that fibrin sealant is very
efficient [12-14,33,34],. Comparison of fibrinogen or
thrombin coated collagen material with surgical swabs
indicated a reduction of blood lost and time to haemosta-
sis when the collagen agent was used [10,11,35,36]. These
data suggest that fibrin sealant is very efficient in the hae-
mostasis of suture hole bleeding but it is expensive and
made from human blood which maybe interfere with
incompatibility and may have the risk of HIV virus and
Hepatitis A contamination. Therefore an effective, absorb-
able, easy to use, medically safe and economic material to
provide fast local haemostasis after arterial bypass anasto-
mosis is demanded. Oxidized regenerated cellulose and
fibrillar collagen are very useful.
Oxidized cellulose seems to confer haemostasis by
decreasing the pH and acting as a caustic, thus generating
an artificial clot. The clot is brownish because of the pro-
duction of acid haematin. Advantage of oxidized cellulose
is its definite and potent action against a wide variety of
pathogenic organisms due to its low pH. Oxidized cellu-
lose does not promote platelet aggregation.Trials 2009, 10:91 http://www.trialsjournal.com/content/10/1/91
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The efficacy of collagen-derived haemostatic agent has
been established in standardized animal studies [9,37-41]
and clinically in man [20,25,42-44]. Collagen induces
haemostasis in two ways, first it activates the aggregation
of thrombocytes and secondly it invokes factor XII (Hage-
mann Factor) which promotes the formation of a fibrin
clot. Advantages of collagen fleece are the fast induction of
haemostasis, low tissue reaction fast absorption and the
possibility that excess collagen can be carefully teased
away from around the haemorrhage site without re-initi-
ating bleeding.
Several authors [20,25,37] have shown the effectiveness
and clinically safety of the collagen fleece, Lyostypt for
topical haemostasis but a direct comparison with oxidized
regenerated cellulose in respect to stop arterial suture hole
bleedings have never been done before.
Therefore COBBANA the first randomized controlled
trial, comparing the haemostatic effect of a collagen based
haemostat (Lyostypt) versus an oxidized cellulose based
haemostat (Surgicel) in arterial bypass anastomosis, was
designed to generate high quality clinical evidence. If sig-
nificant, the results might be generalized and may change
the current treatment practice of suture hole bleedings.
The choice of a one-sided test in lieu of a two sided test is
in need of justification. As Surgicel is the standard device
used in the treatment of suture hole bleeding, the success-
ful rejection of an additional one-sided hypothesis in the
opposite direction (effectively carrying out a two-sided
test at the .05 significance level) would lead to the same
action as the failure to reject the hypothesis in favour of
Lyostypt: Surgicel would remain the product of choice as
a haemostypt for anastomoses. As further action would
not depend on the outcome of the opposite one-sided
test, a one-sided test would be appropriate here. Bland
and Bland [45] discuss that " [...] a one sided test is appro-
priate when a large difference in one direction would lead
to the same action as no difference at all." Bauer and
Köhne [17] suggest one-sided tests for two reasons: Com-
bining two-sided p-values from two different stages of the
trial would defy interpretation if the effects would point in
opposite direction, and the option of stopping for futility
after the first stage would only be available in the case of
results very close to the situation of no effect. Addition-
ally, it is considered a waste of resources and ethically
doubtful to carry on the trial if the intermediate results
favour Surgicel, and the rest of the trial could only be used
to establish the superiority of the standard treatment.
Conclusion
The COBBANA trial is a randomized controlled prospec-
tive study to evaluate the haemostatic effect of Lyostypt
versus Surgicel in arterial bypass anastomosis. As clinical
relevant conclusion the COBBANA trial aims to find out
whether the use of Lyostypt will stop suture hole bleed-
ings significantly faster than Surgicel.
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